Neural Plasticity
2022
Ming-Hao Yang, Zhi-Peng Guo, Xue-Yu Lv et al.
Rumination is a common symptom of major depressive disorder (MDD) and has been characterized as a vulnerability factor for the onset or recurrence of MDD. However, the neurobiological mechanisms underlying rumination and appropriate treatment strategies remain unclear. In the current study, we used resting-state functional magnetic resonance imaging to investigate the effects of body-mind...
Current Topics in Behavioral Neurosciences
2022
Albert Garcia‐romeu, Sean Darcy, Hillary Jackson et al.
Serotonin 2A receptor (5-HT2AR) agonist "classic psychedelics" are drawing increasing interest as potential mental health treatments. Recent work suggests psychedelics can exert persisting anxiolytic and antidepressant effects lasting up to several months after a single administration. Data indicate acute subjective drug effects as important psychological factors involved in observed...
Frontiers in Public Health
2022
Gang Wu, Shanshan Wang, Tingling Wang et al.
The COVID-19 pandemic has a serious impact on the mental health of the public due to its economic and social impact. And psychological effects have led to drug and alcohol abuse. After the city lifted the lockdown, we consecutively encountered several young nitrous oxide abusers admitted to hospital for neurological treatment. To inform physician decisions and social intervention, this...
Topoi
2022
Fredrik Svenaeus
24 citations
In this paper I explore health and illness through the lens of enactivism, which is understood and developed as a bodily-based worldly-engaged phenomenology. Various health theories - biomedical, ability-based, biopsychosocial - are introduced and scrutinized from the point of view of enactivism and phenomenology. Health is ultimately argued to consist in a central world-disclosing aspect of...
Journal of Psychopharmacology
2022
A. H. Young
3 citations
The 21st century has seen a dramatic flow and ebb in the fortunes of clinical psychopharmacology particularly with regard to antidepressants. For about 20 years, perhaps from about 1985 onwards, the tide flowed in with many ‘new’ drugs being made available to clinicians. In mood and psychotic disorders, these were essentially incremental advances from old drugs such as amitriptyline and...
Frontiers in Psychology
2022
Charlotte Grégoire, Nolwenn Marie, Corine Sombrun et al.
20 citations
A symptom cluster is very common among oncological patients: cancer-related fatigue (CRF), emotional distress, sleep difficulties, pain, and cognitive difficulties. Clinical applications of interventions based on non-ordinary states of consciousness, mostly hypnosis and meditation, are starting to be investigated in oncology settings. They revealed encouraging results in terms of improvements...
Psi Chi Journal of Psychological Research
2022
Catherine N. Conway, Lisa E Baker
6 citations
Recent clinical trials indicate favorable therapeutic outcomes of psychedelic-assisted psychotherapy for anxiety and treatment-resistant depression. Whereas the neurobiological systems underlying these effects are not well understood, animal behavioral models can serve to investigate these mechanisms. For the current study, we implemented 2 rodent models predictive of anxiolytic drug effects, a...
2022
Carolina Martins Cabrera
INTRODUÇÃO: A ayahuasca é uma bebida preparada utilizando-se a casca do cipó Banisteriopsis caapi junto com as folhas de Psychotria viridis, apresentando o alcaloide dimetiltriptamina (DMT), responsável pela ativação do receptor serotoninérgico, e as β-carbolinas harmina e harmalina, as quais possuem função de inibição da enzima monoaminoxidase. O decocto, que é tradicionalmente utilizado em...
Revista Virtual de Química
2022
João Pedro Evangelista Ferreira, Stella Bortoli, Airton Vicente Pereira
1 citation
Depression and anxiety disorders are a major challenge for modern psychiatry, especially when shown to be resistant to conventional means of treatment. Over the past decade, psychedelic and entactogen substances, once stigmatized, have regained an ever-growing momentum as potential therapeutic agents for these disorders. The present study offers a review and comparison of the pharmacological...
Proceedings for Annual Meeting of The Japanese Pharmacological Society
2022
Daisuke Ibi
Recently, FDA approved psilocybin, the psychoactive substance found in the magic mushroom, as a "breakthrough therapy" for depression; however, its detailed mechanism remains unknown. Serotonergic psychedelics such as psilocybin and LSD have hallucinatory effect through stimulation of serotonin 5-HT2A receptor (5-HT2A), motivating us to investigate the role of 5-HT2A stimulation in...